AR106487A1 - Antagonistas de receptores de cgrp - Google Patents

Antagonistas de receptores de cgrp

Info

Publication number
AR106487A1
AR106487A1 ARP160103294A ARP160103294A AR106487A1 AR 106487 A1 AR106487 A1 AR 106487A1 AR P160103294 A ARP160103294 A AR P160103294A AR P160103294 A ARP160103294 A AR P160103294A AR 106487 A1 AR106487 A1 AR 106487A1
Authority
AR
Argentina
Prior art keywords
cgrp
receiver antagonists
antagonists
cgrp receiver
cerebrovascular
Prior art date
Application number
ARP160103294A
Other languages
English (en)
Inventor
Stephen Mason Jonathan
Pickworth Mark
Deflorian Francesca
Joanne Bucknell Sarah
Stuart Congreve Miles
Andrew Christopher John
Original Assignee
Heptares Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Heptares Therapeutics Ltd filed Critical Heptares Therapeutics Ltd
Publication of AR106487A1 publication Critical patent/AR106487A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Su uso en el tratamiento, la prevención el mejoramiento, el control o la reducción de trastornos cerebrovasculares o vasculares asociados con la función del receptor del CGRP. Reivindicación 1: Un compuesto de la fórmula (1), o las sales del mismo, en donde R¹ es H o F y Ar¹ es un anillo heterocíclico de 5 miembros opcionalmente sustituido que contiene por lo menos dos átomos de nitrógeno.
ARP160103294A 2015-10-30 2016-10-28 Antagonistas de receptores de cgrp AR106487A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1519194.3A GB201519194D0 (en) 2015-10-30 2015-10-30 CGRP receptor antagonists

Publications (1)

Publication Number Publication Date
AR106487A1 true AR106487A1 (es) 2018-01-17

Family

ID=55130446

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP160103294A AR106487A1 (es) 2015-10-30 2016-10-28 Antagonistas de receptores de cgrp

Country Status (13)

Country Link
US (3) US9688660B2 (es)
EP (1) EP3368526B1 (es)
JP (1) JP6874014B2 (es)
CN (1) CN108430991B (es)
AR (1) AR106487A1 (es)
AU (1) AU2016344689A1 (es)
BR (1) BR112018008416A2 (es)
CA (1) CA3002625A1 (es)
GB (1) GB201519194D0 (es)
IL (1) IL258894A (es)
SG (1) SG11201803382XA (es)
TW (1) TW201722936A (es)
WO (1) WO2017072723A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201519194D0 (en) * 2015-10-30 2015-12-16 Heptares Therapeutics Ltd CGRP receptor antagonists
GB201519196D0 (en) 2015-10-30 2015-12-16 Heptares Therapeutics Ltd CGRP Receptor Antagonists
GB201519195D0 (en) 2015-10-30 2015-12-16 Heptares Therapeutics Ltd CGRP Receptor Antagonists
KR20220114613A (ko) * 2019-12-17 2022-08-17 바이오하벤 파마슈티컬 홀딩 컴퍼니 엘티디. Cgrp 저해제의 비강내 약제학적 조성물
WO2024046223A1 (zh) * 2022-08-30 2024-03-07 熙源安健医药（上海）有限公司 吲唑甲酰胺类衍生物及其制备方法和用途

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2732221B1 (fr) 1995-03-28 1997-04-25 Oreal Utilisation d'un antagoniste de cgrp pour traiter les rougeurs cutanees d'origine neurogene et composition obtenue
CA2262818A1 (en) 1996-09-10 1998-03-19 Dr. Karl Thomae Gesellschaft Mit Beschrankter Haftung Modified amino acids, pharmaceuticals containing these compounds and methods for their production
US20030069231A1 (en) 1999-10-12 2003-04-10 Klaus Rudolf Modified aminoacids, pharmaceuticals containing these compounds and method for their production
US6294534B1 (en) 1998-06-11 2001-09-25 Merck & Co., Inc. Spiropiperidine derivatives as melanocortin receptor agonists
JP2002517444A (ja) 1998-06-11 2002-06-18 メルク エンド カムパニー インコーポレーテッド メラノコルチン受容体作動薬としてのスピロピペリジン誘導体
DE19952146A1 (de) * 1999-10-29 2001-06-07 Boehringer Ingelheim Pharma Arylalkane, Arylalkene und Aryl-azaalkane, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
US20040063735A1 (en) 2002-06-05 2004-04-01 Chaturvedula Prasad V. Calcitonin gene related peptide receptor antagonists
US7220862B2 (en) 2002-06-05 2007-05-22 Bristol-Myers Squibb Company Calcitonin gene related peptide receptor antagonists
US7842808B2 (en) 2002-06-05 2010-11-30 Bristol-Myers Squibb Company Anti-migraine spirocycles
JO2355B1 (en) 2003-04-15 2006-12-12 ميرك شارب اند دوم كوربوريشن Hereditary calcitonin polypeptide receptor antagonists
AR046787A1 (es) 2003-12-05 2005-12-21 Bristol Myers Squibb Co Agentes antimigrana heterociclicos
AU2003297694A1 (en) 2003-12-05 2005-08-12 Bristol-Myers Squibb Company Calcitonin gene related peptide receptor antagonists
TW200533398A (en) 2004-03-29 2005-10-16 Bristol Myers Squibb Co Novel therapeutic agents for the treatment of migraine
DE102004015723A1 (de) 2004-03-29 2005-10-20 Boehringer Ingelheim Pharma Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
US20050233980A1 (en) * 2004-04-20 2005-10-20 Boehringer Ingelheim International Gmbh CGRP-antagonist in combination with a serotonin-reuptake inhibitor for the treatment of migraine
DE102004019492A1 (de) 2004-04-22 2005-11-10 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
DE602005010463D1 (de) 2004-10-13 2008-11-27 Merck & Co Inc Cgrp-rezeptorantagonisten
CA2583534A1 (en) 2004-10-14 2006-04-27 Merck & Co., Inc. Cgrp receptor antagonists
CN101068595A (zh) 2004-10-22 2007-11-07 默克公司 Cgrp受体拮抗剂
EP1770091A1 (de) 2005-09-29 2007-04-04 Boehringer Ingelheim Pharma GmbH & Co. KG CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
US7834007B2 (en) 2005-08-25 2010-11-16 Bristol-Myers Squibb Company CGRP antagonists
WO2007141285A1 (en) 2006-06-08 2007-12-13 Boehringer Ingelheim International Gmbh Treatment of gastrointestinal disorders with cgrp-antagonists
US8044043B2 (en) 2008-04-11 2011-10-25 Bristol-Myers Squibb Company CGRP receptor antagonists
JP2012512834A (ja) * 2008-12-19 2012-06-07 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 炎症、喘息及びｃｏｐｄの処置のためのｃｃｒ２受容体アンタゴニストとしての環状ピリミジン−４−カルボキサミド
US8314117B2 (en) 2009-10-14 2012-11-20 Bristol-Myers Squibb Company CGRP receptor antagonists
US8481546B2 (en) * 2010-03-30 2013-07-09 Bristol-Myers Squibb Company CGRP receptor antagonist
US9174989B2 (en) 2012-05-09 2015-11-03 Merck Sharp & Dohme Corp. Process for making CGRP receptor antagonists
GB201519194D0 (en) * 2015-10-30 2015-12-16 Heptares Therapeutics Ltd CGRP receptor antagonists

Also Published As

Publication number Publication date
GB201519194D0 (en) 2015-12-16
JP6874014B2 (ja) 2021-05-19
BR112018008416A2 (pt) 2018-10-23
CN108430991B (zh) 2021-01-05
IL258894A (en) 2018-06-28
SG11201803382XA (en) 2018-05-30
US10166226B2 (en) 2019-01-01
TW201722936A (zh) 2017-07-01
JP2018532790A (ja) 2018-11-08
US20170121311A1 (en) 2017-05-04
AU2016344689A1 (en) 2018-05-17
EP3368526A1 (en) 2018-09-05
US9925178B2 (en) 2018-03-27
EP3368526B1 (en) 2019-12-25
CA3002625A1 (en) 2017-05-04
US20170239236A1 (en) 2017-08-24
US9688660B2 (en) 2017-06-27
CN108430991A (zh) 2018-08-21
US20180153876A1 (en) 2018-06-07
WO2017072723A1 (en) 2017-05-04

Similar Documents

Publication Publication Date Title
AR106487A1 (es) Antagonistas de receptores de cgrp
UY36684A (es) Agonistas de triazol del receptor apj
SV2018005723A (es) Derivados de tiohidantoina substituidos como antagonistas del receptor de androgenos
BR112018008423A2 (pt) antagonistas do receptor cgrp
CL2017003032A1 (es) Derivado de pirido[3,4-d]pirimidina y sal farmacéuticamente aceptable de éste
CO2017002160A2 (es) Derivados de pirimidina sustituidos con heterociclilo opcionalmente condensados útiles para el tratamiento de enfermedades inflamatorias, metabólicas, oncológicas y autoinmunitarias
MX2018008815A (es) Inhibidores de tirosina quinasa de bruton.
EA201992147A1 (ru) Ингибиторы тирозинкиназы брутона
BR112015029495A2 (pt) compostos heterocíclicos como inibidores da via de sinalização hedgehog
EA201890156A1 (ru) Антагонисты рецептора cgrp
EA201990158A1 (ru) Производные бензодиоксана и их фармацевтическое применение
CL2016000325A1 (es) Antagonistas de vía para tratar trastornos del sueño por cambio de fase
MX2020003507A (es) Compuestos pirimidinicos inhibidores de (tbk)/(ikk) epsilon y usos de los mismos.
AR106488A1 (es) Antagonistas de receptores de cgrp
LT3625221T (lt) 3-metilpirolidin-2,5-diono dariniai, naudotini kaip cgrp receptoriaus antagonistai
CL2017002163A1 (es) Derivado de imidazopirimidina e imidazotriazina, y composición farmacéutica que lo comprende.
UY37339A (es) Formas de sal de 4-ciano-n-(2-(4,4-dimetilciclohex-1-en-1-il)-6-(2,2,6,6-tetrametiltetrahidro-2h-piran-4-il)piridin-3-il)-1himidazol-2-carboxamida y composiciones que las contienen
EA033085B1 (ru) Производные 2-(1-гетероарилпиперазин-4-ил)метил-1,4- бензодиоксана в качестве альфа2c-антагонистов
PH12017501214A1 (en) Cgrp antagonist peptides
MX2019007786A (es) Compuestos sustituidos de guanidina.
CL2018001871A1 (es) Uso de inhibidores de la actividad o función de pi3k para el tratamiento del síndrome de sjögren primario
PL410019A1 (pl) Syntetyczna pochodna aromatyczna i jej zastosowanie do zapobiegania lub leczenia grzybic, zwłaszcza wywołanych Candida spp.
EA201992475A1 (ru) КОМБИНАЦИЯ, СОДЕРЖАЩАЯ ТАКОЙ АГОНИСТ PPAR, КАК ЭЛАФИБРАНОР, И ИНГИБИТОР АЦЕТИЛ-КоА-КАРБОКСИЛАЗЫ (АКК)
AU201812171S (en) Side table
UA108342U (uk) 7-н-бутил-8-n,n-діетиламіноетиламіно-3-метилксантину сукцинат, який виявляє діуретичну та аналгетичну дію

Legal Events

Date Code Title Description
FB Suspension of granting procedure